Comparison of the effects of low-dose hydrocortisone and Xuebijing injection on acute lung injury in rats

doi:10.3877/cma.j.issn.1674-0785.2017.11.006

Abstract

Abstract:

Objective

To investigate the efficacy of low-dose hydrocortisone and Xuebijing injection on acute lung injury (ALI) induced by Escherichia coli (E.coli) in rats.

Methods

ALI model was induced in Wistar rats by intratracheal E.coli injection [3 ml/kg, O₁₁₁B₄, (4.4~5.6)×10¹²CFU/L], twelve hours later the survived rats were randomly divided into hydrocortisone group (HC) treated with hydrocortisone for two days [5 mg/(kg?d), intraperitoneally], Xuebijing group (X) treated with Xuebijing injection for two days [5 ml/(kg?d), intraperitoneally], and ALI control group (C) treated with normal saline for two days (5 ml/(kg?d), intraperitoneally). And there was a normal control group (N) that received intratracheal E.coli (3 ml/kg) injection and was treated with intraperitoneal normal saline for two days [5 ml/(kg?d)]. Twelve hours after the treatment the rats were killed, and the levels of TNF- and IL-8 in serum were measured by ELASA, then the lung index was calculated.

Results

There was no difference in mortality among group HC, X and C (χ²=0.194, P=1.000). The levels of TNF- in serum in group HC and X [(80.31±11.87) ng/L and (89.42±22.76) ng/L, respectively] were significantly lower than that in group C [(125.68±27.91) ng/L] (P<0.05), but there was no significant difference between group HC and X (P>0.05); IL-8 in group HC and X [(175.01±40.29) ng/L and (214.38±56.03) ng/L, respectively] were significantly lower than that in group C [(266.48±56.09) ng/L] (P<0.05), but there was no significant difference between group HC and X (P>0.05); The lung index in group HC and X [(0.318±0.058)% and (0.352±0.046)%, respectively] were significantly lower than that in group C [(0.412±0.055)%] (P<0.05), but there was no significant difference between group HC and X (P>0.05).

Conclusion

Both low-dose hydrocortisone and Xuebijing injection can inhibit the production of pro-inflammatory cytokines and attenuate pulmonary edema in rats with E.coli-induced ALI with similar effects.

Key words: Acute lung injury, Hydrocortisone, Xuebijing injection, Cytokine, Rat

Linying Guo, Hongri Li, Qi Zhang, Xiaodai Cui, Guowei Song. Comparison of the effects of low-dose hydrocortisone and Xuebijing injection on acute lung injury in rats[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(11): 1889-1893.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.11.006

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I11/1889

Figures/Tables 1

References 33

[1]	Erickson S, Schibler A, Numa A, et al. Acute lung injury in pediatric intensive care in Australia and New Zealand: a prospective, multicenter, observational study [J]. Pediatr Crit Care Med, 2007, 8(4): 317-323.
[2]	李红日，宋国维，甘小庄, 等. 内源性急性肺损伤大鼠模型的建立 [J]. 中国小儿急救医学, 2010, 17(1): 40-42.
[3]	喻文亮，陆铸今，王莹, 等. 小儿急性呼吸窘迫综合征前瞻性多中心临床流行病学研究 [J]. 中华急诊医学杂志, 2005, 14(6): 448-453.
[4]	Cheifetz IM. Pediatric acute respiratory distress syndrome [J]. Respir Care, 2011, 56(10): 1589-1599.
[5]	DiBlasi RM, Cheifetz IM. Neonatal and pediatric respiratory care: what does the future hold? [J]. Respir Care, 2011, 56(9): 1466-1480.
[6]	Raghavendran K, Willson D, Notter RH. Surfactant therapy for acute lung injury and acute respiratory distress syndrome [J]. Crit Care Clin, 2011, 27(3): 525-559.
[7]	Puntorieri V, Hiansen JQ, McCaig LA, et al. The effects of exogenous surfactant administration on ventilation-induced inflammation in mouse models of lunginjury [J]. BMC Pulm Med, 2013, 13: 67.
[8]	Fuller BM, Mohr NM, Dettmer M, et al. Mechanical ventilation and acute lung injury in emergency department patients with severe sepsis and septic shock: an observational study [J]. Acad Emerg Med, 2013, 20(7): 659-669.
[9]	Ried M, Bein T, Philipp A, et al. Extracorporeal lung support in trauma patients with severe chest injury and acute lung failure: a 10-year institutional experience [J]. Crit Care, 2013, 17(3): R110.
[10]	Hodgson CL, Tuxen DV, Davies AR, et al. A randomised controlled trial of an open lung strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome [J]. Crit Care, 2011, 15(3): R133.
[11]	Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome [J]. Crit Care, 2013, 17(5): R253.
[12]	Hall MW, Geyer SM, Guo CY, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study [J]. Crit Care Med, 2013, 41(1): 224-236.
[13]	Bouros D, Alexandrakis MG, Antoniou KM, et al. The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Acute Respiratory Distress Syndrome [J]. BMC Pulm Med, 2004, 4(6): 1-9.
[14]	Ware LB. Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design [J]. Crit Care Med, 2005, 33(3): S217-222.
[15]	Hagau N, Slavcovici A, Gonganau DN, et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection [J]. Crit Care, 2010, 14(6): R203.
[16]	Yang G, Hamacher J, Gorshkov B, et al. The Dual Role of TNF in Pulmonary Edema [J]. J Cardiovasc Dis Res, 2010, 1(1): 29-36.
[17]	Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology [J]. Respir Res, 2006, 7: 125.
[18]	Kambas K, Markiewski MM, Pneumatikos IA, et al. C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome [J]. J Immunol, 2008, 180(11): 7368-7375.
[19]	Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury [J]. Chest, 2010, 137(2): 288-296.
[20]	Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis [J]. Int J Inflam, 2011, 2011: 908468.
[21]	Samransamruajkit R, Jiraratanawong K, Siritantiwat S, et al. Potent inflammatory cytokine response following lung volume recruitment maneuvers with HFOV in pediatric acute respiratory distress syndrome [J]. Asian Pac J Allergy Immunol, 2012, 30(3): 197-203.
[22]	de Pablo R, Monserrat J, Prieto A, et al. Role of circulating soluble chemokines in septic shock [J]. Med Intensiva, 2013, 37(8): 510-518.
[23]	Roch A, Hraiech S, Dizier S, et al. Pharmacological interventions in acute respiratory distress syndrome [J]. Ann Intensive Care, 2013, 3(1): 20.
[24]	Thompson BT. Corticosteroids for ARDS [J]. Minerva Anestesiol, 2010, 76(6): 441-447.
[25]	Araz O, Demirci E, Yilmazel Ucar E, et al. Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study [J]. Multidiscip Respir Med, 2013, 8(1): 74.
[26]	Azoulay É, Canet E, Raffoux E, et al. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia [J]. Eur Respir J, 2012, 39(3): 648-653.
[27]	Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome [J]. N Engl J Med, 2006, 354(16): 1671-1684.
[28]	Annane D, Sébille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome [J]. Crit Care Med, 2006, 34(1): 22-30.
[29]	Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis [J]. BMJ, 2008, 336(7651): 1006-1009.
[30]	付国强，曹义战，仲月霞, 等. 血必净注射液对急性百草枯中毒大鼠肺、血浆TNF-α和IL-10的影响 [J]. 中华急诊医学杂志, 2013, 22(11): 1226-1228.
[31]	周厚荣，张谦，郭军, 等. 血必净对急性呼吸窘迫综合征大鼠炎性因子及肺气-血屏障变化的影响 [J]. 中华急诊医学杂志, 2011, 20(10): 1071-1074.
[32]	陈云霞，李春盛. 血必净治疗脓毒症的随机对照多中心临床研究 [J]. 中华急诊医学杂志, 2013, 22(2): 130-135.
[33]	赵森伟，柴艳芬. 血必净与低分子肝素对严重脓毒症患者凝血功能及预后的影响 [J]. 中华急诊医学杂志, 2011, 20(4): 405-408.

组别	开始例数	存活例数	TNF-α（ng/L）	IL-8（ng/L）	肺指数（%）
HC组	13	9	80.31±11.87^ab	175.01±40.29^ab	0.318±0.058^ab
X组	14	10	89.42±22.76^ab	214.38±56.03^ab	0.352±0.046^ab
C组	12	8	125.68±27.91^a	266.48±56.09^a	0.412±0.055^a
N组	8	8	41.04±16.43	63.29±19.21	0.170±0.023
F值			22.88	28.364	38.391
P值			<0.001	<0.001	<0.001

组别	开始例数	存活例数	TNF-α（ng/L）	IL-8（ng/L）	肺指数（%）
HC组	13	9	80.31±11.87^ab	175.01±40.29^ab	0.318±0.058^ab
X组	14	10	89.42±22.76^ab	214.38±56.03^ab	0.352±0.046^ab
C组	12	8	125.68±27.91^a	266.48±56.09^a	0.412±0.055^a
N组	8	8	41.04±16.43	63.29±19.21	0.170±0.023
F值			22.88	28.364	38.391
P值			<0.001	<0.001	<0.001

Please choose a citation manager

Content to export